Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study
ABSTRACTObjective Gain or amplification 1q21 (1q21+) is one of the most common recurrent cytogenetic abnormalities in multiple myeloma (MM). Our aim was to explore the presentation and outcomes of patients with MM harboring 1q21 + .Methods We retrospectively analyzed the clinical features and surviv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2177979 |
| _version_ | 1797905042231001088 |
|---|---|
| author | Haimin Chen Nian Zhou Haotian Shi Wenjun Yu Lixia Wu Fan Zhou |
| author_facet | Haimin Chen Nian Zhou Haotian Shi Wenjun Yu Lixia Wu Fan Zhou |
| author_sort | Haimin Chen |
| collection | DOAJ |
| description | ABSTRACTObjective Gain or amplification 1q21 (1q21+) is one of the most common recurrent cytogenetic abnormalities in multiple myeloma (MM). Our aim was to explore the presentation and outcomes of patients with MM harboring 1q21 + .Methods We retrospectively analyzed the clinical features and survival outcomes in 474 consecutive patients with MM receiving immunomodulatory drugs or proteasome inhibitor-based regimens as first-line therapies.Results 1q21 + was detected in 249 (52.5%) patients. Patients with 1q21 + had a higher proportion of subtypes of IgA, IgD, and λ-light chain than non-1q21 + . 1q21 + was associated with more advanced ISS stage and was more frequently accompanied by del(13q), elevated lactate dehydrogenase and lower levels of hemoglobin and platelets. Patients with 1q21 + had shorter PFS (21 months vs. 31 months, P = 0.001) and OS (43 months vs. 72 months, P < 0.001) than those without 1q21 + . Multivariate Cox regression analysis confirmed that 1q21 + was an independent prognostic factor for both PFS (HR 1.277, P = 0.031) and OS (HR 1.547, P = 0.003). Patients with 1q21 + del(13q) double-abnormality had shorter PFS (P < 0.001) and OS (P = 0.001) than those with no FISH abnormalities, and they also had shorter PFS (P = 0.018) and OS (P = 0.026) than those with del(13q) single abnormality. No significant difference in PFS (P = 0.525) or OS (P = 0.245) was found between patients with 1q21 + del(13q) double-abnormality and 1q21 + del(13q) multiple-abnormality.Conclusions Patients with 1q21 + were more likely to have coexisting negative clinical features and del(13q). 1q21 + was an independent prognostic factor associated with poor outcomes. Concurrence with such unfavorable features may account for poor outcomes given 1q21 + . |
| first_indexed | 2024-04-10T09:58:46Z |
| format | Article |
| id | doaj.art-55f5cc112352481395ba3aadba8f5529 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-04-10T09:58:46Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-55f5cc112352481395ba3aadba8f55292023-02-16T11:27:13ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2177979Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center studyHaimin Chen0Nian Zhou1Haotian Shi2Wenjun Yu3Lixia Wu4Fan Zhou5Department of Hematology and Oncology, Shanghai Jing’an District Zhabei Central Hospital, Shanghai, People’s Republic of ChinaDepartment of Hematology and Oncology, Shanghai Jing’an District Zhabei Central Hospital, Shanghai, People’s Republic of ChinaDepartment of Hematology and Oncology, Shanghai Jing’an District Zhabei Central Hospital, Shanghai, People’s Republic of ChinaDepartment of Hematology and Oncology, Shanghai Jing’an District Zhabei Central Hospital, Shanghai, People’s Republic of ChinaDepartment of Hematology and Oncology, Shanghai Jing’an District Zhabei Central Hospital, Shanghai, People’s Republic of ChinaDepartment of Hematology and Oncology, Shanghai Jing’an District Zhabei Central Hospital, Shanghai, People’s Republic of ChinaABSTRACTObjective Gain or amplification 1q21 (1q21+) is one of the most common recurrent cytogenetic abnormalities in multiple myeloma (MM). Our aim was to explore the presentation and outcomes of patients with MM harboring 1q21 + .Methods We retrospectively analyzed the clinical features and survival outcomes in 474 consecutive patients with MM receiving immunomodulatory drugs or proteasome inhibitor-based regimens as first-line therapies.Results 1q21 + was detected in 249 (52.5%) patients. Patients with 1q21 + had a higher proportion of subtypes of IgA, IgD, and λ-light chain than non-1q21 + . 1q21 + was associated with more advanced ISS stage and was more frequently accompanied by del(13q), elevated lactate dehydrogenase and lower levels of hemoglobin and platelets. Patients with 1q21 + had shorter PFS (21 months vs. 31 months, P = 0.001) and OS (43 months vs. 72 months, P < 0.001) than those without 1q21 + . Multivariate Cox regression analysis confirmed that 1q21 + was an independent prognostic factor for both PFS (HR 1.277, P = 0.031) and OS (HR 1.547, P = 0.003). Patients with 1q21 + del(13q) double-abnormality had shorter PFS (P < 0.001) and OS (P = 0.001) than those with no FISH abnormalities, and they also had shorter PFS (P = 0.018) and OS (P = 0.026) than those with del(13q) single abnormality. No significant difference in PFS (P = 0.525) or OS (P = 0.245) was found between patients with 1q21 + del(13q) double-abnormality and 1q21 + del(13q) multiple-abnormality.Conclusions Patients with 1q21 + were more likely to have coexisting negative clinical features and del(13q). 1q21 + was an independent prognostic factor associated with poor outcomes. Concurrence with such unfavorable features may account for poor outcomes given 1q21 + .https://www.tandfonline.com/doi/10.1080/16078454.2023.2177979Multiple myelomagain/amplification 1q21del(13q)PFSOS |
| spellingShingle | Haimin Chen Nian Zhou Haotian Shi Wenjun Yu Lixia Wu Fan Zhou Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study Hematology Multiple myeloma gain/amplification 1q21 del(13q) PFS OS |
| title | Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study |
| title_full | Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study |
| title_fullStr | Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study |
| title_full_unstemmed | Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study |
| title_short | Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study |
| title_sort | presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies results from a single center study |
| topic | Multiple myeloma gain/amplification 1q21 del(13q) PFS OS |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2177979 |
| work_keys_str_mv | AT haiminchen presentationandoutcomesofpatientswithmultiplemyelomaharboringgainoramplificationof1q21andreceivingnovelagenttherapiesresultsfromasinglecenterstudy AT nianzhou presentationandoutcomesofpatientswithmultiplemyelomaharboringgainoramplificationof1q21andreceivingnovelagenttherapiesresultsfromasinglecenterstudy AT haotianshi presentationandoutcomesofpatientswithmultiplemyelomaharboringgainoramplificationof1q21andreceivingnovelagenttherapiesresultsfromasinglecenterstudy AT wenjunyu presentationandoutcomesofpatientswithmultiplemyelomaharboringgainoramplificationof1q21andreceivingnovelagenttherapiesresultsfromasinglecenterstudy AT lixiawu presentationandoutcomesofpatientswithmultiplemyelomaharboringgainoramplificationof1q21andreceivingnovelagenttherapiesresultsfromasinglecenterstudy AT fanzhou presentationandoutcomesofpatientswithmultiplemyelomaharboringgainoramplificationof1q21andreceivingnovelagenttherapiesresultsfromasinglecenterstudy |